Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 8 recruiting now early-phase tilt small index

Metastatic Uveal Melanoma: early-phase trial registry

8 of 15 indexed Metastatic Uveal Melanoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,140 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

15 US clinical trials · 8 currently recruiting · #1,140 of 28,707 conditions by registered trial count

Metastatic Uveal Melanoma: 15 US clinical trials tracked, 8 recruiting.

Metastatic Uveal Melanoma is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 3 of these trials.

Enrollment posture brief

Registry condition metastatic-uveal-melanoma

OPEN 8 | RECR 53% | LATE 0 | EARLY 15 | RANK #1140 | SPON 3

Volume-matched condition peers

Nearest open-share peer: Beta-Thalassemia (53% recruiting · 15 trials)

Advanced Lung Non-Small Cell53.3%Metastatic Uveal Melanom (th…53%AIDS26.7%Adult Acute Myeloid Leukemia0%Adult Glioblastoma0%
Open-enrollment share among volume-matched conditions near Metastatic Uveal Melanoma

Metastatic Uveal Melanoma lists 8 open slots (53% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Metastatic Uveal Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Metastatic Uveal Melanoma is recruiting above its size-band peers.

    8 of 15 indexed trials (53.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Metastatic Uveal Melanoma research.

    H. Lee Moffitt Cancer Center and Research Institute accounts for 3 of 15 trials (20%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Most Metastatic Uveal Melanoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 15 trials that report a genuine target (sentinel values excluded). 10 of those (66.7%) plan for fewer than 100 participants.

  4. Metastatic Uveal Melanoma research is mostly interventional.

    15 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 17Phase 28

Open and recent trials

15 total, page 1 of 1

RECRUITING Phase 1 336 participants

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

IDEAYA Biosciences

NCT03947385
RECRUITING Phase 2 280 participants

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Replimune

NCT06581406
RECRUITING Phase 1 109 participants

Tebentafusp-tebn With LDT in Metastatic UM

Thomas Jefferson University

NCT06626516
RECRUITING Phase 1 36 participants

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

Novelwise Pharmaceutical Corporation

NCT07136181
RECRUITING Phase 2 32 participants

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

H. Lee Moffitt Cancer Center and Research Institute

NCT06121180
RECRUITING Phase 2 30 participants

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

University of Miami

NCT06627244
RECRUITING Phase 1 30 participants

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

Memorial Sloan Kettering Cancer Center

NCT05607095
RECRUITING Phase 2 18 participants

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

H. Lee Moffitt Cancer Center and Research Institute

NCT07276386
ACTIVE NOT RECRUITING Phase 2 420 participants

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

IDEAYA Biosciences

NCT05987332
ACTIVE NOT RECRUITING Phase 1 352 participants

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

M.D. Anderson Cancer Center

NCT05075993
ACTIVE NOT RECRUITING Phase 1 71 participants

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

M.D. Anderson Cancer Center

NCT03025256
ACTIVE NOT RECRUITING Phase 1 66 participants

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

Novartis Pharmaceuticals

NCT05415072
ACTIVE NOT RECRUITING Phase 2 40 participants

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

National Cancer Institute (NCI)

NCT01587352
ACTIVE NOT RECRUITING Phase 2 28 participants

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

Thomas Jefferson University

NCT04728633
ACTIVE NOT RECRUITING Phase 2 7 participants

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

H. Lee Moffitt Cancer Center and Research Institute

NCT05170334

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 8

Top Sponsors

H. Lee Moffitt Cancer Center and Research Institute 3 trials
IDEAYA Biosciences 2 trials
Thomas Jefferson University 2 trials
M.D. Anderson Cancer Center 2 trials
Novelwise Pharmaceutical Corporation 1 trials
Replimune 1 trials
Novartis Pharmaceuticals 1 trials
National Cancer Institute (NCI) 1 trials
University of Miami 1 trials
Memorial Sloan Kettering Cancer Center 1 trials

Named interventions

Most-linked intervention names on Metastatic Uveal Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Crizotinib Drug
2 trials
Binimetinib Drug
2 trials
IDE196 Drug
2 trials
Tebentafusp Drug
2 trials
Nivolumab Biological
2 trials
DYP688 Drug
1 trials
LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide Drug
1 trials
LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel Drug
1 trials

US sites by state

Facility locations filed on Metastatic Uveal Melanoma trials. A trial with sites in several states counts in each.

New York 7 trials
Florida 6 trials
Pennsylvania 4 trials
Colorado 4 trials
California 4 trials
Texas 3 trials
Tennessee 3 trials
Massachusetts 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Metastatic Uveal Melanoma page

15 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Uveal Melanoma condition card totals 15 registered trials; most-linked intervention Crizotinib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.